The effect of misclassification on sample size for one and two-sample tests with binary endpoints.

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Péter Hársfalvi, Jenő Reiczigel
{"title":"The effect of misclassification on sample size for one and two-sample tests with binary endpoints.","authors":"Péter Hársfalvi, Jenő Reiczigel","doi":"10.1080/10543406.2024.2444231","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years, an increasing number of publications on the analysis of binary data have applied methods that take misclassification into account. However, potential misclassification is often ignored in study design due to the lack of sample size formulas or software. This may lead to a considerable loss of power in studies that only account for misclassification at the analysis stage. We argue that analyses correcting for misclassification should be used in combination with appropriate sample size adjustment in the design phase of the studies. We illustrate the importance of this by comparing the required sample sizes with and without misclassification, and provide an appropriate sample size procedure implemented as an R function for the one-sample and two-sample tests for binary endpoints. The sample size is calculated from the presumed binomial parameters (<i>p</i><sub>0</sub> and <i>p</i><sub><i>a</i></sub> for one-sample and <i>p</i><sub>1</sub> and <i>p</i><sub>2</sub> for two-sample tests), the required power, and the probabilities of correct classification, sensitivity (<i>Se)</i>, and specificity (<i>Sp)</i>. Our results show that misclassification may drastically affect the necessary sample size in both testing scenarios.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-12"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2024.2444231","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

In recent years, an increasing number of publications on the analysis of binary data have applied methods that take misclassification into account. However, potential misclassification is often ignored in study design due to the lack of sample size formulas or software. This may lead to a considerable loss of power in studies that only account for misclassification at the analysis stage. We argue that analyses correcting for misclassification should be used in combination with appropriate sample size adjustment in the design phase of the studies. We illustrate the importance of this by comparing the required sample sizes with and without misclassification, and provide an appropriate sample size procedure implemented as an R function for the one-sample and two-sample tests for binary endpoints. The sample size is calculated from the presumed binomial parameters (p0 and pa for one-sample and p1 and p2 for two-sample tests), the required power, and the probabilities of correct classification, sensitivity (Se), and specificity (Sp). Our results show that misclassification may drastically affect the necessary sample size in both testing scenarios.

双终点单样本和双样本检验中误分类对样本量的影响。
近年来,越来越多的关于二进制数据分析的出版物采用了考虑误分类的方法。然而,由于缺乏样本量公式或软件,在研究设计中往往会忽略潜在的错误分类。这可能会导致在分析阶段只考虑错误分类的研究的相当大的功率损失。我们认为,在研究的设计阶段,纠正错误分类的分析应与适当的样本量调整相结合。我们通过比较有和没有错误分类所需的样本量来说明这一点的重要性,并提供一个适当的样本量程序,作为二元端点的单样本和双样本测试的R函数实现。样本量是根据假定的二项参数(单样本试验为p0和pa,双样本试验为p1和p2)、所需功率以及正确分类的概率、灵敏度(Se)和特异性(Sp)计算的。我们的结果表明,在两个测试场景中,错误分类可能会极大地影响必要的样本量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信